All News

fence

The Fallacy of Biologic Treatment to Prevent Rheumatoid Arthritis

d Richard Conway, MBBChBAO, PhD

The window of opportunity concept in RA shifted our focus to trying to treat disease earlier and more aggressively to improve long term outcomes. A natural development of this was to reconsider the possibility of therapeutic interventions aimed at the prevention of rheumatoid arthritis.

Read Article
psA.fil_.Hands_.jpg

Bimekizumab is Coming… in Third Place

d Michael Putman, MD, MSCI

Of the many exciting advancements for patients with psoriatic arthritis at ACR Convergence, one upcoming therapy stood out: the dual IL-17A/F inhibitor bimekizumab. Nearly two dozen bimekizumab abstracts will be featured at this year’s meeting and it recently received authorization in Europe and the U.S. for psoriasis. That makes this the year I plan to figure out where this drug will be useful for my patients with PsA. 

Read Article
lung%2Cbright.jpg

Pulmonary Manifestations of Rheumatic Disease in Asymptomatic Patients

d Meral K. El Ramahi, MD, FACP, FACR

In clinical practice, pulmonary manifestations of rheumatic medical diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and peripheral spondyloarthritis (pSpA) are typically not screened for upon diagnosis of a rheumatic disease in patients without any signs or symptoms suggest

Read Article
steroids.prednisone.pills_.jpg

Glucocorticoids-free zone in SLE?

d Md Yuzaiful Md Yusof, MRCP(UK), PhD

For over 70 years, glucocorticoids, (GC) have been a part of standard therapy in SLE. They are classically used to not only induce remission or treat an acute flare, but also as maintenance therapy. They are a valuable 'friend' if used wisely, and can become a 'foe' if used excessively.

Read Article
Q&A from RA-ILD Guidelines Presentation: Q: "Why was AZA recommended but ABA was not?" A: "The evidence was not as good for it so it was not included" Can anyone explain this to me? Where is this amazing data for AZA in RA-ILD? @RheumNow #ACR23

Mike Putman EBRheum ( View Tweet)

#ACR23 Year in Review. CAR-T cell showed promising results in #SLE based on case series but extrapolation to other RMD may be challenging. -Myositis recurred after 7days, needing MMF -No improvement in lung fibrosis #SSc Longer-term data & trial data are needed @RheumNow https://t.co/4Zmjvr51Ab
Md Yuzaiful Md Yusof  ( View Tweet)
More good data for benralizumab (IL5i) in EGPA, @TerrierBen There may be additional benefit over MEPO given deeper eosinophil depletion Checkout our recent editorial about this in @TheLancetRheum @RheumNow #ACR23 https://t.co/1d2nITOuOs
Mike Putman EBRheum ( View Tweet)
Our work showed the PSAID-12 score done remotely correlated with in-person clinic assessment of tender (r=0.58) , swollen joint count (r= 0.51), pain (r=0.84). 21% of patients had low disease activity onPSAID12 assessment, Chan A #Abst0507 #ACR23 @RheumNow https://t.co/vorth2ko39 https://t.co/Q2Y3ApD47E
Dr. Antoni Chan  ( View Tweet)
Why do we do translational research? Dr Mustelin outlines different goals of basic science in #yearinreview I would emphasize the #1: understanding pathogenesis is key to address clinical challenges Overall “we have much more work to do than we care to admit” @RheumNow #ACR23 https://t.co/QtBO3Go3gD
Aurelie Najm  ( View Tweet)
Year in review: Long-term outcome of pts in the MAINRITSAN trials Better outcome in pts who received RTX every 6 months for 18 months. Implications? May consider shorter duration of maintenance tx (<36mos)? #ACR23 @RheumNow #vasculitis https://t.co/18cXBlfxSG
sheila  ( View Tweet)
Great Dr. Seo presents a great quote from Prof Seza Ozen during #ACR23 YiR "What you think of as a rare manifestation of a common disease is probably a common presentation of a disease you are not aware of (yet.)" A call to arms to continue to be curious! @RheumNow https://t.co/zVcIpHZznt
Dr. Rachel Tate  ( View Tweet)
RTX-induction subgroup, ADVOCATE Encouraging results (remission 71% vs 56% plbo wk 52), but never forget RTX was NOT redosed at month 6, so pts randomized to prednisone had NO TREATMENT from wk 20 - wk 52 Take results w/grain of salt @RheumNow #ACR23 #ACRBest @anisha_dua https://t.co/zVhRX3IbiL
Mike Putman EBRheum ( View Tweet)
Regarding monitoring of ILD: "TLC takes a lot of time and is not necessary for follow up PFTs" @sclerodermaUM Very nice pearl; I have been including TLC in subsequent PFTs, probably not necessary Will change my practice immediately & save patients time @RheumNow #ACR23

Mike Putman EBRheum ( View Tweet)

The gut matters and take care of your dental health! #Yearinreview Microbiomes and RA: 1. Changing gut micro biome in mice immediately triggers inflammatory arthritis 2. Mucosal breaks allow bacteria in and trigger citrullination. #ACR23 @RheumNow https://t.co/Iini9yE8dJ
TheDaoIndex KDAO2011 ( View Tweet)
#ACR23 Year in Review. Dr Seo did a great job in highlighting key papers. #SLE #Tyk2 Phase 2 RCT of Deucravacitinib recruited pts of diverse ancestry. More pts on DEUC met SRI-4 response vs PBO. Question remains about the inverse/flat dose response. Going to Phase 3 @RheumNow https://t.co/68rYjEnWyN
Md Yuzaiful Md Yusof  ( View Tweet)
More studies emphasizing the role of microbiome in RA 1- Directly arthritogenic microbe strain confirmed in mice model 2- Gingivitis and oral microbiome can trigger citrullination and ACPA production Dr Tomas Mustelin #yearinreview @RheumNow #ACR23 https://t.co/uBd1UEgLRz
Aurelie Najm  ( View Tweet)
Vitamin D and bone health 🦴 Dr. Connie Weaver discusses the effect of Vit D on bone as well as dietary recomms fr diff groups. Are your pts at risk of Vit d deficiency?👇 #ACR23 @RheumNow @rheumarhyme https://t.co/XcopyBHAoj
sheila  ( View Tweet)
Delighted to be joining my colleagues below to reporting on #ACR23 for @Rheumnow. Tune-in for coverage and follow my colleagues below as well! https://t.co/rdLZbPGj3O https://t.co/hhwYf4YyLv
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Where does CAR-T fit in the future landscape? Dr. Seo reviews two case studies that question additional questions regarding efficacy, longevity of efficacy, and additional questions necessary to answer for our patients. #ACR23 @RheumNow https://t.co/mi4Z1tuJIV
Dr. Rachel Tate  ( View Tweet)
Half a pizza > once a week might help RA! Type of pizza matters as it is the ingredients- fresh mozzarella, olive oil are main ingredients #NotDominoes #YearinReview @RheumNow #acr23 https://t.co/i86JtUhXwW
TheDaoIndex KDAO2011 ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×